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All phases of lipopolysaccharide (LPS)-induced fever are mediated by prostaglandin (PG) E2. It is known that the second
febrile phase (which starts at ;1.5 h post-LPS) and subsequent phases are mediated by PGE2 that originated in
endotheliocytes and perivascular cells of the brain. However, the location and phenotypes of the cells that produce
PGE2 triggering the first febrile phase (which starts at ;0.5 h) remain unknown. By studying PGE2 synthesis at the
enzymatic level, we found that it was activated in the lung and liver, but not in the brain, at the onset of the first phase
of LPS fever in rats. This activation involved phosphorylation of cytosolic phospholipase A2 (cPLA2) and transcriptional
up-regulation of cyclooxygenase (COX)-2. The number of cells displaying COX-2 immunoreactivity surged in the lung
and liver (but not in the brain) at the onset of fever, and the majority of these cells were identified as macrophages.
When PGE2 synthesis in the periphery was activated, the concentration of PGE2 increased both in the venous blood
(which collects PGE2 from tissues) and arterial blood (which delivers PGE2 to the brain). Most importantly,
neutralization of circulating PGE2 with an anti-PGE2 antibody both delayed and attenuated LPS fever. It is concluded
that fever is initiated by circulating PGE2 synthesized by macrophages of the LPS-processing organs (lung and liver) via
phosphorylation of cPLA2 and transcriptional up-regulation of COX-2. Whether PGE2 produced at the level of the
blood–brain barrier also contributes to the development of the first phase remains to be clarified.
Citation: Steiner AA, Ivanov AI, Serrats J, Hosokawa H, Phayre AN, et al. (2006) Cellular and molecular bases of the initiation of fever. PLoS Biol 4(9): e284. DOI: 10.1371/journal.
pbio.0040284
Introduction
Fever is an ancient host-defense response and a common
symptom of infection and systemic inﬂammation. Since
Milton and Wendlandt [1] discovered the pyrogenic activity
of prostaglandins (PGs) of the E series, and Vane [2] found
that nonsteroidal anti-inﬂammatory drugs block fever by
inhibiting PG synthesis, it has been accepted that fever is
mediated by PGs, speciﬁcally PGE2 [3–6]. PGE2 synthesis
occurs in three steps: (1) membrane phospholipids are
converted to arachidonic acid by phospholipase A2 (PLA2);
(2) arachidonic acid is converted to PGH2 by cyclooxygenase
(COX); and (3) PGH2 is isomerized to PGE2 by a terminal PGE
synthase (PGES) [6,7]. It has been shown in rats [8–14] and
mice [15,16] that COX-2 and microsomal PGES-1 (mPGES-1)
are transcriptionally up-regulated in endothelial and peri-
vascular cells of brain microvessels between 1.5 and 12 h after
administration of pyrogenic doses of bacterial lipopolysac-
charide (LPS). Furthermore, Scammell et al. [17] have shown
that microinjection of the COX inhibitor ketorolac into the
preoptic region attenuates the febrile response over 1.5–6 h
after intravenous (i.v.) injection of LPS in rats. These results
indicate that febrigenic PGE2 is produced centrally.
It should be considered, however, that the initiation of
fever precedes by approximately 1 h the earliest time point at
which PGE2-synthesizing enzymes have been shown to be up-
regulated in the brain. In a thermoneutral environment, i.v.
LPS typically causes in rats and mice a polyphasic fever, and
the ﬁrst phase of this response starts at approximately 0.5 h
post-LPS [18,19]. Because the ﬁrst phase is sensitive to
ambient temperature and can be readily masked by the stress
hyperthermia associated with animal handling and LPS
injection [19,20], this phase often escapes detection and
remains the least studied component of the febrile response.
The ﬁrst phase of LPS fever was not investigated in any of the
abovementioned studies of the source of febrigenic PGE2.W e
[21–23] and others [24–26] have hypothesized that, unlike the
second and subsequent febrile phases, the ﬁrst phase of fever
is triggered by peripherally produced PGE2. Over the last two
decades, several studies have attempted to test this hypoth-
esis, but the results obtained have been inconclusive, contra-
dictory, or incomplete (for details, see Results and
Discussion). In particular, the location (inside or outside the
brain) and phenotypes of the cells involved in the initiation of
fever are unknown, as are the steps of the PGE2-synthesizing
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PLoS BIOLOGYcascade that are initially activated to trigger the fever
response. By closing these gaps, the present study identiﬁes
the cellular and molecular bases of the initiation of fever.
Results/Discussion
The question as to whether peripherally (i.v. or intra-
arterially) administered PGE2 causes fever remains contro-
versial. Although there are reports of peripherally injected
PGE1 and PGE2 being pyrogenic in several species of
laboratory animals [24,27], there are at least as many
documented failures to induce fever by peripheral admin-
istration of PGE [24,28,29]. The latter, negative results can be
explained, at least partially, as due to self-aggregation of PGE
in aqueous solutions and the subsequent loss of biological
activity. Indeed, PGE2 was found to be highly pyrogenic in
rabbits when infused in an albumin-bound (monomeric), but
not in a free (aggregated) form [21]. Albumin is the principal
carrier of PGE2 in the circulation, and up to 99% of
circulating PGE2 is albumin-bound [30].
In the present study, a 2:1 (molar ratio) PGE2–albumin
complex was prepared by adding PGE2 (all reagents are from
Sigma-Aldrich, St. Louis, Missouri, United States, unless
speciﬁed otherwise) and bovine serum albumin (BSA) to
pyrogen-free saline, and then sonicating this mixture for 3
min and incubating it at 37 8C for 1 h. In a thermoneutral
environment, the rats were infused i.v. with BSA-bound PGE2
(280 or 560 lg/kg, 100 ll/kg/min, 10 min). Based on the
assumptions that PGE2 is evenly distributed in the extrac-
ellular compartment (20% of the body mass) and that its half-
life is 1 min [31], it can be estimated that the protocol used
elevates the plasma concentration of PGE2 by 350 pg/ml (low
dose) or 700 pg/ml (high dose) at 12 min after the beginning
of infusion. These concentrations are within the physiological
range [24,32]. Whereas BSA had no thermoregulatory effect,
the PGE2–BSA complex caused a dose-dependent rise in deep
body (colonic) temperature (Tc;F i g u r e1 A ) .T h i sf e v e r
response was brought about, at least in part, by tail skin
vasoconstriction, as evident from a decrease in the heat loss
index (the quotient of two temperature gradients: skin-
ambient/colonic-ambient [33]). Hence, when administered in
its most relevant form (albumin complex) and at physiolog-
ically relevant doses, peripheral PGE2 is pyrogenic in rats.
How circulating, albumin-bound PGE2 causes fever re-
mains speculative. Activation of vagal afferents by PGE2 has
been proposed [34], but the fact that vagotomy does not
affect the ﬁrst febrile phase (for discussion, see [35,36]) makes
this mechanism unlikely. An alternative scenario seems more
plausible. Binding to albumin prevents the rapid enzymatic
inactivation of PGE2 [37,38], thus allowing it to reach a
distant site. A good candidate for such a site is the preoptic
hypothalamus, which is highly sensitive to the pyrogenic
effect of PGE2 [39]. Once dissociated from albumin at the
target site, PGE2 may be carried into the brain tissue by
transporters expressed at the blood–brain barrier (BBB)
[6,26,40]. It should be noted, however, that this scenario is
speculative and needs to be tested experimentally.
Having shown that peripheral PGE2 is pyrogenic in rats, we
asked whether blood levels of PGE2 are elevated at the onset
of the ﬁrst phase of LPS fever. Fever was induced by
administering 0111:B4 Escherichia coli LPS (10 lg/kg) non-
stressfully via the extension of a preimplanted venous
(jugular) catheter to rats kept in a thermoneutral environ-
Figure 1. Circulating PGE2 Initiates LPS Fever in Rats: Circumstantial Evidence
(A) The effects of i.v. infusion (horizontal bar) of BSA-bound PGE2 or BSA on Tc and heat loss index of rats kept at a neutral ambient temperature (30 8C).
(B) The effects of i.v. bolus injection (arrow) of LPS or saline on the same parameters.
Change in Tc was calculated by subtracting the Tc value at a given point from that at the start of infusion or injection (time zero). In (A), the absolute Tcs
at time zero were 38.3 6 0.1 8C, 38.5 6 0.1 8C, and 38.4 6 0.2 8C for the groups treated with BSA and with the lower and higher doses of BSA-bound
PGE2, respectively. In (B), initial Tcs were 38.2 6 0.1 8C and 38.3 6 0.1 8C for the groups treated with saline and LPS, respectively. The heat loss index was
calculated as a quotient of two temperature gradients: skin-ambient and colonic-ambient; this index varies between 0 (maximal vasoconstriction) and 1
(maximal vasodilation) [33].
(C) The levels of PGE2 in the venous and arterial blood of rats 40 min after i.v. injection of LPS or saline at thermoneutrality. This time point corresponds
to the maximal thermoeffector activity (minimal heat loss index) to produce the first phase of LPS fever as shown in (B). All doses are indicated. Means
6 SE are presented. The number of rats in each group (n) is indicated. An asterisk (*) indicates a significant difference from the BSA- or saline-treated
group (p , 0.05; two-way analysis of variance for repeated measures followed by the Tukey test in [A] and [B]; Student t-test in [C]).
DOI: 10.1371/journal.pbio.0040284.g001
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How Fever Is Initiatedment (see Materials and Methods for details). The ﬁrst febrile
phase started at approximately 30-min post-LPS and was
brought about, at least partially, by tail skin vasoconstriction
(Figure 1B). At 40 min (the time corresponding both to the
maximal rate of rise in body temperature and to the maximal
thermoeffector activity that underlies this rise), samples of
venous and arterial blood were collected from LPS-treated
(febrile) and saline-treated (afebrile) rats, and the concen-
tration of PGE2 in the venous and arterial blood was
measured by enzyme immunoassay. The venous blood gathers
PGE2 synthesized in the tissues, and the arterial blood delivers
it to the brain, the presumptive site of the febrigenic action of
circulating PGE2 [39]. Consistent with the marked catabolism
of PGE2 in the lungs [41], the level of PGE2 was lower in the
arterial than in the venous blood plasma in both afebrile and
febrile rats (Figure 1C). However, both the venous and
arterial concentrations of PGE2 were substantially (;2.5
times) higher in the febrile rats as compared to the afebrile
controls. These data show that the level of circulating PGE2,
most importantly in the arterial blood, is increased at the
onset of the ﬁrst febrile phase.
Several studies aimed at determining the source of
febrigenic PGE2 have compared the antipyretic effects of
nonsteroidal anti-inﬂammatory drugs administered periph-
erally (i.v. or intraperitoneally) and centrally (intracerebro-
ventricularly [i.c.v.]). The drugs used included indomethacin
[25], nimesulide [32], and keterolac (present study; unpub-
lished data). All these studies faced multiple methodological
problems, including acute thermoregulatory effects of the
drug administered i.c.v. (present study), the ability of drugs to
cross the BBB, and consequently, their tendency to be
distributed evenly between the peripheral compartment
and the brain [32]. We proposed [6] that selective neutraliza-
tion of circulating PGE2 using an antibody is a better
approach to test the hypothesis that peripherally produced
PGE2 initiates fever. Being large proteins (160 kDa), anti-
bodies cannot cross the BBB; this eliminates uncertainty
common in experiments involving nonsteroidal anti-inﬂam-
matory drugs. The antibody used in the present study was
raised against a PGE2–BSA complex in rabbits. It displayed a
high afﬁnity to PGE2 (association constant of 6.3 3 10
10 M
 1,
as determined by Scatchard plot) and a low cross-reactivity
with other prostanoids (,15% for PGF1a and PGB2, and ,9%
for PGA2, PGF2a, and PGB1). The rats were pretreated i.v.
with the anti-PGE2 antibody (neat antiserum; 100 ll/kg/min,
120 min) or with normal rabbit serum, and LPS was injected
18 h later, i.e., at the time when the injected antibody is
expected to achieve a steady-state level in the circulation [42].
The results of this experiment are shown in Figure 2A–2C.
The antibody (but not normal serum) suppressed the ﬁrst
phase of LPS fever: both the rise in Tc and the associated
decrease in the heat loss index were delayed and signiﬁcantly
attenuated (Figure 2A). Immediately after the temperature
response was recorded, a sample of venous blood and the
whole brain (cleared of blood) were collected for immunoen-
zymatic determination of the anti-PGE2 antibody. The anti-
body was found at a high concentration in the blood plasma,
but was below the detection limit in the brain tissue (Figure
2C). To rule out the possibility that a minute, undetectable
amount of antibody in the brain might have accounted for
the suppression of fever, we administered a low dose (2.7 ll/
min, 15 min) of the anti-PGE2 antibody or normal serum
i.c.v., and injected the rats with LPS 18 h later. The rats
injected with the anti-PGE2 antibody i.c.v. had a detectable
Figure 2. Circulating PGE2 Initiates LPS Fever in Rats: Direct Evidence
(A) The effects of i.v. infusion (100 ll/kg/min, 120 min) of the anti-PGE2 antibody or normal serum 18 h before the experiment (pretreatment) on the Tc
and heat loss index responses of rats injected (arrow) with LPS at thermoneutrality (30 8C).
(B) The effects of the i.c.v. infusion (2.7 ll/min, 15 min) of the same anti-PGE2 antibody or normal serum 18 h before the experiment (pretreatment) on
the same responses. Note that the i.c.v. infusion was aimed at testing whether minute amounts of the antibody in the brain are sufficient to suppress
LPS fever (and not at testing whether fever is altered by neutralization of PGE2 in the brain).
Change in Tc was calculated by subtracting the Tc value at a given point from that at the time of injection (time zero). In (A), the absolute Tcs at time
zero were 38.2 6 0.1 8C and 38.1 6 0.2 8C for the groups treated with i.v. normal serum and antibody, respectively. In (B), the initial Tcs were 38.4 6 0.1
8C and 38.2 6 0.2 8C for the groups treated with i.c.v. normal serum and antibody, respectively.
(C) The levels of anti-PGE2 antibody in the blood plasma and whole brain of rats pretreated with i.v. or i.c.v. antibody. Blood samples and brains were
collected immediately after the temperature responses were recorded, i.e., approximately 20 h after pretreatment with the antibody. Antibody levels
(means 6 SE) are expressed as microgram of neat antibody per gram of either plasma or brain tissue. The detection limit for each assay and the number
of rats in each group (n) are indicated. An asterisk (*) indicates a significant difference from the group pretreated with normal serum (p , 0.05; two-way
analysis of variance for repeated measures followed by the Tukey test).
DOI: 10.1371/journal.pbio.0040284.g002
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How Fever Is Initiatedlevel of the antibody in the brain (Figure 2C), but their febrile
response to LPS was unaffected (Figure 2B). A large fraction
of the antibody given i.c.v. leaked into the blood, presumably
reﬂecting the asymmetric nature of the BBB (its major role is
to limit transport in the blood-to-brain direction, but not in
the opposite direction) or possibly because the BBB was
breached in this experimental group by the implanted i.c.v.
cannula. Importantly, however, the plasma antibody concen-
tration in the rats treated with the i.c.v. antibody was
approximately 60 times lower than that in the rats treated
with the i.v. antibody (Figure 2C). It is concluded that minute
amounts of the anti-PGE2 antibody in the brain (even when
detectable) are not sufﬁcient to suppress the initiation of
fever, and that the cause of the delayed and attenuated ﬁrst
febrile phase observed in the rats pretreated with i.v.
antibody was neutralization of PGE2 outside the BBB.
Having demonstrated that circulating PGE2 is indeed
responsible, at least partially, for triggering LPS-induced
fever, we investigated which step of the PGE2 biosynthetic
pathway is activated at the onset of the febrile response.
Previously, we reported that the onset of the ﬁrst phase of
LPS fever is associated with large increases of COX-2 and
mPGES-1 mRNAs in the lung and liver and with a moderate
increase of COX-2 (but not mPGES-1) mRNA in the
hypothalamus [22]. However, it remained to be determined
whether the observed transcriptional changes translate into
changes in the corresponding protein contents at such an
early time point (40 min) after LPS administration. We had
Figure 3. Mechanism of Activation of PGE2 Synthesis at the Onset of LPS Fever in Rats
Tissue contents of the following proteins are shown: IjB-a (an inhibitor of nuclear factor-jB), three PGE2-synthesizing enzymes (p-cPLA2, COX-2, and
mPGES-1), and b-actin (a ‘‘housekeeping’’ protein). These proteins were determined by Western blot in the lung, liver, and hypothalamus. The tissue
samples were collected 40 min after i.v. injection of LPS (10 lg/kg) or saline at thermoneutrality. This time point corresponds to the maximal
thermoeffector activity to produce the first phase of LPS fever (see Figure 1B). Electrophoretograms of two representative animals from each group are
shown on top. The expression of each protein of interest (relative to the expression of b-actin) is shown on bottom (means 6 SE); the number of rats (n)
is shown in parenthesis. An asterisk (*) indicates a significant difference from the saline-treated group (p , 0.05; Student t-test).
DOI: 10.1371/journal.pbio.0040284.g003
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How Fever Is Initiatedalso shown [22] that neither cytosolic PLA2-a (cPLA2-a) nor
either of the two secretory PLA2 studied (II and V) is
transcriptionally up-regulated at the onset of fever. This
ﬁnding, however, does not exclude the possibility that cPLA2
is activated posttranscriptionally by phosphorylation, the
principal mechanism of activation for this enzyme [43]. In the
present study, we determined the contents of phosphorylated
cPLA2 (p-cPLA2), COX-2, and mPGES-1 proteins by Western
blot in the lung, liver, and hypothalamus at 40 min after
injection of LPS or saline, a time that corresponds to the
onset of the ﬁrst febrile phase in LPS-treated rats (Figure 1B).
COX-2–positive cells were also studied in all three tissues by
immunohistochemistry using two different protocols of
sample preparation (see Material and Methods). None of
the enzymes studied was increased at the protein level in the
hypothalamus of the LPS-treated rats as compared to the
saline-treated controls (Figure 3). Neither did the immuno-
histochemical analysis reveal any increase in the number of
COX-2–positive hypothalamic cells at the onset of fever,
although the same antibody readily detected a surge in the
number of COX-2–positive endotheliocytes in the hypothala-
mic microvasculature at later stages of LPS fever, in both the
Figure 4. Identification of the Pulmonary and Hepatic Cells Producing PGE2 at the Onset of LPS Fever in Rats
Immunolocalization of COX-2 in the lung and liver and identification of the cell types expressing this enzyme. Top row: tissue localization of COX-2
(green immunofluorescence) in the lung and liver of rats at 40 min after i.v. injection of saline or at the onset of the first febrile phase (i.e., 40 min after
i.v. injection of LPS, 10 lg/kg) at thermoneutrality. Next rows: dual localization of LPS-induced COX-2–immunoreactivity (green; left column) with either
the macrophage marker ED2 or the endothelial cell marker RECA1 (red; middle column) in the lung and liver at the onset of the first febrile phase.
Doubly labeled cells appear yellow in the merged confocal images (right column). White arrows and black arrowheads mark examples of doubly and
singly (COX-2 only) labeled cells, respectively. Scale bars represent 40 lm.
DOI: 10.1371/journal.pbio.0040284.g004
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How Fever Is Initiatedpresent study (positive controls; unpublished data) and
previous studies [11,12]. In the lung, LPS increased the
contents of p-cPLA2 and COX-2 (Figure 3), and augmented
the number of cells containing COX-2 (Figure 4), but did not
alter the protein level of constitutively expressed mPGES-1
(Figure 3). In the liver, the immunohistochemical analysis
(which is more sensitive) revealed a surge in the number of
COX-2–positive cells at the onset of fever (Figure 4), whereas
the Western blot analysis (less sensitive) found a tendency for
an increase in the overall content of COX-2 and no changes
in the content of either p-cPLA2 or mPGES-1 (Figure 3). We
also found that inﬂammatory signaling (assessed by a decrease
in the content of the nuclear factor-jB inhibitor, IjB-a [44])
was activated in the lung and liver, but not in the
hypothalamus, at the onset of LPS fever (Figure 3).
These results show that the onset of the ﬁrst febrile phase is
associated with activation of inﬂammatory signaling and
increased PGE2 synthesis in the periphery. The early
activation of PGE2 synthesis involves phosphorylation of
cPLA2 (lung) and transcriptional up-regulation of COX-2
(lung and liver). Transcriptional up-regulation is the main
(although not the only [45,46]) mechanism of activation for
this enzyme [6,7]. Hence, the increased circulating level of
PGE2 at the onset of the ﬁrst febrile phase may be explained
by the following enzymatic events in the lung and liver:
production of arachidonic acid by activated (phosphorylated)
cPLA2 ! conversion of arachidonic acid to PGH2 by up-
regulated COX-2 ! isomerization of PGH2 into PGE2 by
constitutively expressed mPGES-1. Whereas the physiological
importance of cPLA2 and mPGES-1 in the ﬁrst febrile phase
remains to be conﬁrmed in studies with pharmacological or
genetic blockade of these enzymes, the indispensable role of
COX-2 (and the uninvolvement of COX-1) in the ﬁrst phase
of LPS fever have been demonstrated in our recent study in
knockout mice [47].
Preferential location of the synthesis of febrigenic PGE2 in
the liver and lungs (but not in the brain) deserves special
discussion. The fact that the i.v. antibody attenuated the ﬁrst
febrile phase but did not abolish it completely (Figure 2A)
may be due to incomplete neutralization of circulating PGE2.
However, it may also reﬂect a contribution of centrally
produced PGE2 (e.g., by a small number of hypothalamic cells
that express COX-2 constitutively) to the development of the
ﬁrst phase of LPS fever. Although we cannot rule out such a
contribution, it is noteworthy that multiple methods used in
our present and previous [22] studies (Table 1) found a
profound activation of PGE2 synthesis in the periphery, but
hardly any signs (none at the protein level) of activation of
hypothalamic PGE2 synthesis.
To identify the pulmonary and hepatic producers of PGE2,
we ﬁrst determined how the cells that become COX-2 positive
at the onset of LPS fever relate to the histological elements
revealed by eosin staining; this analysis was performed in
freshly frozen samples. In the lung, COX-2–positive cells were
found to cluster around alveoli, often forming what looked
like cell chains (unpublished data). In the liver, the
parenchyma did not stain for COX-2, and the vast majority
of COX-2–positive cells were located in the stromal compart-
ment, often in close proximity to sinusoids. Some COX-2–
positive cells were also found around the central vein (a small
vein that gathers the blood from sinusoids) and in the visceral
peritoneum covering the liver (unpublished data). We then
double-stained lung and liver for COX-2 and either the
macrophage marker ED2 [48] or the endothelial marker
RECA1 [49]; this analysis was performed in paraformalde-
hyde-ﬁxed samples (Figure 4). In the lung, 89 6 6% (mean 6
standard error [SE] of ﬁve samples) of COX-2–positive cells
were macrophages (ED2 positive), and 11% were unidentiﬁed
(ED2 and RECA1 negative). In the liver, 83 6 2% of the COX-
2–positive cells were macrophages (ED2 positive), 9 6 1%
were endotheliocytes (RECA1 positive), and 8% remained
unidentiﬁed. The key role of macrophages in the initiation of
fever agrees with our recent ﬁnding that the ﬁrst febrile
phase depends entirely on the recognition of LPS (via the
Toll-like receptor-4) by bone marrow-derived cells [50].
In summary, the present study shows that the ﬁrst phase of
LPS fever is initiated (at least partially) by PGE2 that
originated in peripheral tissues. Activation of PGE2 synthesis
at the onset of the ﬁrst phase of LPS fever involves
phosphorylation of cPLA2, transcriptional up-regulation of
COX-2, and possibly other mechanisms. The vast majority of
the PGE2-producing cells are macrophages. These ﬁndings
challenge the predominant view that fever is initiated
exclusively by inﬂammatory mediators produced at the level
of the BBB. These ﬁndings, however, do not contradict the
principal role of the centrally produced PGE2 in the second
and subsequent febrile phases.
Materials and Methods
Animals. The study was conducted in male Long-Evans rats
weighing 300–400 g (Charles River, Wilmington, Massachusetts,
United States). The rats were habituated (seven daily training sessions,
4 h each) to spending time in artiﬁcial ‘‘rat holes,’’ cylindrical
conﬁners made of stainless steel wire [20,22,23]. The same conﬁners
were used later in the experiments. Each rat was used in only one
experiment. The protocols were approved by the St. Joseph’s Hospital
Animal Care and Use Committee.
Surgery and instrumentation. Under ketamine-xylazine-aceproma-
zine anesthesia (55.6, 5.5, and 1.1 mg/kg, respectively, intraperito-
neally) and antibiotic (enroﬂoxacin, 1.1 mg/kg, subcutaneously)
protection, each rat was subjected to chronic catheterization of the
jugular vein as described elsewhere [22]. The catheters were ﬂushed
with heparinized (10 U/ml) saline on Days 1 and 3 postsurgery. The
experiments were performed on Day 5. On the day of the experiment,
each rat was placed in a wire conﬁner and equipped with two copper-
constantan thermocouples: one for recording Tc and the other for
Table 1. Inflammatory Signaling and PGE2 Synthesis Are
Selectively Activated at the Onset of the First Phase of LPS Fever
in the Periphery (Lung and Liver) but Not in the Brain
(Hypothalamus)
Parameter Studied (Method) Periphery
a Brain
a
NFjB (decrease in IjB-a; Western) þþ  
p-cPLA2 (Western) þ/  
COX-2 (RT-PCR)
b þþ þ
COX-2 (Western) þ/  
COX-2 (immunohistochemistry) þþ  
mPGES-1 (RT-PCR)
b þþ  
aEffects revealed: A minus sign ( ) indicates no effect; a plus sign (þ) indicates a significant
increase ( 3-fold); two plus signs (þþ) indicate a significant increase (.3-fold); and a plus/
minus sign (þ/ ) indicates a significant increase ( 3-fold) in one but not the other of the
two peripheral organs studied.
bData from [22].
DOI: 10.1371/journal.pbio.0040284.t001
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How Fever Is Initiatedrecording tail skin temperature. The colonic thermocouple was
inserted 10 cm beyond the anal sphincter and ﬁxed to the base of the
tail with adhesive tape. The skin thermocouple was positioned at the
boundary of the proximal and middle thirds of the tail, on its lateral
surface, and was insulated from the environment with tape. The
thermocouples were plugged in to a data logger (Cole-Parmer,
Vernon Hills, Illinois, United States), which was connected to a
personal computer. The rats in their conﬁners were placed in a
climatic chamber (Forma Scientiﬁc, Marietta, Ohio, United States) set
to a neutral ambient temperature of 30.0 8C. Their jugular catheters
were extended with lengths of PE-50 tubing ﬁlled with saline, thus
permitting i.v. drug administration to be performed in a stress-free
fashion, from outside the chamber.
Tissue harvesting. Immediately before collection of blood and
tissue specimens, the rats were anesthetized with ketamine-xylazine-
acepromazine (5.56, 0.55, and 0.11 mg/kg, respectively, i.v.). Blood
samples were collected either from the inferior vena cava (venous
blood) or left ventricle (arterial blood). Each sample was transferred
to an eppendorf tube containing EDTA and indomethacin (ﬁnal
concentrations: 1 mg/ml and 10 lM, respectively). The collected blood
was immediately centrifuged (3,000 g, 10 min, 4 8C), and the resulting
plasma was stored at  80 8C.
For collection of tissue samples for the immunoassay and Western
blot protocols, each rat was perfused through the left ventricle (right
atrium cut) with 100 ml of 10 mM phosphate-buffered saline (PBS; pH
7.4). The right medial lobe of the liver, the medial lobe of the right
lung, and either the hypothalamus (for Western blot) or the entire
brain were collected rapidly and snap frozen in liquid nitrogen. The
samples were stored at  80 8C.
Tissue specimens for the immunohistochemistry protocols were
collected using two methods. For immunohistochemical analysis of
freshly frozen (non-ﬁxed) tissues, a rat was perfused with PBS (50 ml).
The liver, right lung, and brain were excised, frozen in dry ice
powder, and stored at  80 8C. The specimens were cryosectioned
(section thickness, 14 lm) immediately before the analysis. For
immunohistochemical analysis of ﬁxed tissues, a rat was perfused with
50 ml of heparinized (10 U/ml) PBS followed by 200 ml of a 4%
paraformaldehyde solution in PBS. The liver, right lung, and brain
were excised, postﬁxed in the paraformaldehyde solution for 2 h,
transferred to PBS containing 20% sucrose, and kept in this solution
at 4 8C for 24 h. The specimens were then frozen, cryosectioned
(section thickness, 30 lm), and immediately subjected to the
immunohistochemical analysis.
Immunoassays. PGE2 was measured in plasma by enzyme immuno-
assay using a commercially available kit (Cayman, Ann Arbor,
Michigan, United States); the samples were prepared according to
the manufacturer’s instructions. The levels of anti-PGE2 antibody in
the plasma and brain were assayed by enzyme immunoassay involving
a conjugate of four proteins: goat anti-mouse IgG (which coated all
wells of a 96-well plate), mouse anti-rabbit IgG, rabbit anti-PGE2 IgG
(sample or standard), and PGE2-horseradish peroxidase complex
(Amersham, Piscataway, New Jersey, United States). The conjugate
was developed by adding the peroxidase substrate 3,39,5,59-tetrame-
thylbenzidine; the reaction product had maximal absorbance at 630
nm. Samples of blood plasma were diluted (1:256) in 100 mM Tris-
buffered saline (pH 7.4) before the assay. Each brain was homogen-
ized in 4 ml of a 100 mM NaOH solution containing 0.2% sodium
dodecyl sulfate. After the homogenate was cleared by centrifugation
(14,000 g, 10 min, 6 8C), the supernatant was neutralized with 100 mM
HCl and diluted (1:10) with Tris-buffered saline. The detection limits
for blood plasma (4 lg/g) and brain tissue (1 lg/g) were determined as
the triple noise-level concentrations.
Western blot. The Western blot protocol was identical to that used
to measure IjB-a and b-actin in our earlier study [51], except that
here we also measured p-cPLA2, COX-2, and mPGES-1. The following
primary rabbit polyclonal antibodies were used (dilutions indicated):
anti-IjB-a (1:1,000; Cell Signaling, Beverly, Massachusetts, United
States), anti-b-actin (1:1,000), anti–p-cPLA2 (1:500; Cell Signaling),
anti–COX-2 (1:1,000; Cayman), and anti-mPGES-1 (1:1,000; Cayman).
The primary antibodies revealed immunoblot bands corresponding
to the following molecular masses: 36 kDa for IjB-a; 42 kDa for b-
actin; 105 kDa for p-cPLA2; 72 kDa for COX-2; and 16 kDa for
mPGES-1.
Immunohistochemistry. Single immunoﬂuorescence was used to
visualize and localize COX-2–positive cells in freshly frozen [11,12] or
paraformaldehyde-ﬁxed [52] samples of lung, liver, and hypothal-
amus. Dual immunoﬂuorescence protocols were used to verify co-
localization of COX-2 with ED2 (a macrophage marker) or RECA1 (an
endotheliocyte marker) in paraformaldehyde-ﬁxed samples of lung
and liver [52]. The fraction of COX-2–immunoreactive cells that were
also immunoreactive to ED2 or RECA1 was determined in serial (10–
15) sections (30 lm-thick) collected at 150-lm intervals through the
right lobe of the liver or right lung. Images of merged confocal
channels were collected from 104-lm
2 ﬁelds (nine for each section).
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